570:
be effective and safe in inducing prolonged remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. This effect is particularly shown in children who have rituximab resistance or relapse after rituximab. The tolerance profile of
Obinutuzumab is comparable to rituximab. Similar promising results is shown in adults with Membranoproliferative glomerulonephritis treated with Obinutuzumab after resistance to rituximab, tacrolimus and cyclophosphamide. Furthermore, Obinutuzumab showed sustained clinical benefit through 2 years in patients with class III and IV Proliferative Lupus Nephritis compared to rituximab.
5506:
569:
Obinutuzumab is recently reported to be safe and effective in some autoimmune diseases affecting the kidneys. It is a promising treatment of renal diseases with proteinuria, in particular patients with resistance or partial response to rituximab. A single low-dose infusion of
Obinutuzumab, found to
560:
In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each). More than 20% of subjects had abnormal
1575:
1571:
844:
1646:
248:
1273:
Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (February 1999). "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity".
1140:
Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, et al. (December 2023). "Obinutuzumab in
Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children".
692:
was $ CDN 5,275.54 per 1,000 mg vial. At the recommended dose obinutuzumab costs $ 15,826.50" for the first 28-day cycle and "$ 5275.50 per 28 day cycle for subsequent cycles."
203:
468:
685:
1487:
1457:
684:
In their final recommendation of obinutuzumab, in the
January 2015 Pan-Canadian Oncology Drug Review (pERC) for treatment of chronic lymphocytic leukemia, published by the
885:
3077:
1639:
1318:
5526:
98:
1360:
769:
681:
would not fund use of the drug, due to data uncertainties in Roche's application. In June 2015, NICE announced that it would fund restricted use of the drug.
836:
4074:
1632:
1067:
554:
1546:
643:
Roche developed the drug in the US through its US subsidiary, Genentech, and in Japan through its
Japanese subsidiary, Chugai. Genentech partnered with
5536:
135:
36:
1536:"Final Recommendation for Obinutuzumab (Gazyva) for CLL Pan-Canadian Oncology Drug Review (pERC) Meeting: December 18, 2014; Early Conversion: pCODR"
1425:
4990:
3486:
2638:
2281:
789:
1042:
1335:
5531:
4018:
3687:
561:
lab tests including low calcium and sodium, high potassium, increases in serum creatinine and liver function tests, and low albumin levels.
3907:
3070:
1774:
918:
3544:
3471:
3376:
2752:
637:
614:
519:. One more recent study has shown deeper and longer-lasting remissions through fixed-duration treatment regimens in combination with
4933:
4303:
3401:
734:
As of 2014 clinical trials had been conducted exploring the use of obinutuzumab as a second line monotherapy in relapsed/refractory
1479:
1422:"FDA approves Gazyva for chronic lymphocytic leukemia: Drug is first with breakthrough therapy designation to receive FDA approval"
1447:
4067:
2172:
1698:
877:
5342:
3063:
233:
116:
1315:
3386:
632:
Obinutuzumab was created by scientists at GlycArt
Biotechnology, which had been founded in 2000 as a spin-out company of the
3491:
747:
5496:
4139:
3350:
2518:
735:
719:
711:
663:
655:
516:
365:
152:
4248:
4060:
4035:
1675:
2699:
766:
1513:
4118:
3129:
2824:
2673:
2422:
1924:
1336:"Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research"
723:
4796:
3594:
2149:
2015:
1728:
648:
130:
1601:
5176:
2159:
1685:
1059:
1535:
5171:
4023:
3990:
3931:
3882:
3797:
3421:
1655:
598:
189:
1421:
4976:
4402:
4083:
3961:
3951:
3921:
3712:
3657:
3584:
3574:
3451:
2527:
2010:
1739:
808:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
5541:
5163:
3936:
3925:
3887:
3777:
3762:
3692:
3672:
3667:
3446:
3200:
2085:
2025:
1995:
1898:
1734:
1624:
1036:
696:
4052:
3787:
3647:
3416:
3381:
1940:
1835:
1672:
807:
793:
739:
667:
618:
291:
196:
1572:"FDA Approves Ibrutinib/Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia"
4384:
3902:
3872:
3867:
3852:
3682:
3529:
3481:
3441:
3086:
2793:
2060:
2050:
1870:
1613:
1339:
743:
704:
602:
531:
496:
309:
46:
29:
3140:
5333:
4434:
3624:
3175:
3135:
2448:
2090:
2080:
2065:
1985:
1452:
1403:
1298:
1255:
579:
163:
5373:
5231:
1361:
Presentation: GlycArt
Biotechnology AG From Inception to trade sale – and what happened after...
5383:
5069:
4510:
499:
used as a treatment for cancer. It was originated by GlycArt
Biotechnology AG and developed by
5338:
5328:
4129:
4087:
3511:
3330:
2125:
1395:
1290:
1247:
1212:
1161:
1122:
1017:
978:
689:
500:
80:
910:
5134:
5037:
4700:
4596:
1965:
1807:
1802:
1387:
1282:
1239:
1202:
1192:
1157:
1149:
1112:
1102:
1009:
968:
960:
410:
318:
283:
374:
5510:
5433:
5318:
1543:
Pan-Canadian
Oncology Drug Review via Canadian Agency for Drugs and Technologies in Health
1322:
773:
5323:
5191:
4839:
4673:
4652:
4648:
4644:
4272:
4109:
4029:
3995:
3662:
2902:
2800:
2748:
2346:
1659:
1207:
1180:
1117:
1090:
973:
948:
624:
Details of the antibody's structure are disclosed in the 2008 WHO INN naming proposal.
997:
996:
Fischer K, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M, et al. (4 June 2019).
949:"Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia"
5520:
5473:
5403:
5313:
5220:
5006:
4706:
4628:
4580:
4560:
4418:
4334:
4185:
4151:
3877:
3732:
3285:
3120:
2959:
2849:
2811:
2788:
2720:
2715:
2705:
2481:
2477:
2465:
2272:
2055:
2020:
1840:
1820:
1230:
Ratner M (January 2014). "Genentech's glyco-engineered antibody to succeed
Rituxan".
594:
261:
1407:
1302:
1259:
108:
5483:
5443:
5428:
5423:
5139:
5089:
5084:
5064:
4944:
4939:
4802:
4735:
4711:
4658:
4535:
4525:
4344:
4261:
4256:
4214:
4167:
4124:
4091:
3892:
3857:
3842:
3837:
3832:
3802:
3757:
3752:
3747:
3742:
3727:
3614:
3589:
3569:
3431:
3396:
3335:
3315:
3125:
3110:
3055:
2999:
2984:
2954:
2934:
2816:
2764:
2725:
2613:
2592:
2499:
2461:
2362:
2337:
2333:
2217:
2182:
2135:
2120:
2075:
1950:
1920:
1663:
1181:"New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?"
1091:"New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?"
700:
659:
527:
512:
216:
211:
837:"Prescription medicines: registration of new chemical entities in Australia, 2014"
1153:
5478:
5418:
5408:
5398:
5298:
5288:
5278:
5273:
5238:
5149:
5144:
5119:
5109:
5099:
5074:
5059:
5054:
5012:
4982:
4968:
4963:
4949:
4892:
4850:
4845:
4831:
4826:
4812:
4792:
4745:
4721:
4679:
4663:
4634:
4618:
4586:
4570:
4565:
4540:
4490:
4480:
4475:
4470:
4459:
4449:
4354:
4266:
4224:
4209:
4203:
4199:
4146:
4000:
3974:
3969:
3941:
3917:
3912:
3847:
3822:
3812:
3782:
3772:
3737:
3722:
3707:
3697:
3677:
3652:
3637:
3609:
3559:
3554:
3549:
3534:
3524:
3501:
3496:
3466:
3411:
3355:
3345:
3320:
3310:
3305:
3300:
3275:
3250:
3240:
3235:
3230:
3220:
3205:
3190:
3185:
3170:
3165:
3155:
3150:
3145:
3115:
3029:
3009:
3004:
2994:
2974:
2949:
2944:
2927:
2875:
2865:
2860:
2855:
2757:
2684:
2654:
2649:
2644:
2628:
2618:
2598:
2473:
2469:
2457:
2453:
2382:
2286:
2232:
2227:
2192:
2130:
2115:
2105:
2100:
2095:
2070:
2035:
1990:
1970:
1960:
1915:
1880:
1860:
1816:
1779:
1767:
1762:
1724:
1708:
678:
644:
610:
550:
1378:
Cameron F, McCormack PL (January 2014). "Obinutuzumab: first global approval".
5468:
5463:
5448:
5388:
5378:
5363:
5358:
5353:
5303:
5293:
5283:
5248:
5226:
5212:
5124:
5114:
5104:
5094:
5079:
5022:
5017:
4996:
4911:
4906:
4864:
4858:
4759:
4716:
4612:
4602:
4555:
4545:
4520:
4515:
4505:
4500:
4495:
4485:
4444:
4429:
4424:
4408:
4349:
4329:
4278:
4238:
4219:
4161:
3946:
3897:
3862:
3792:
3767:
3717:
3702:
3642:
3632:
3604:
3579:
3519:
3461:
3456:
3391:
3371:
3325:
3295:
3290:
3280:
3270:
3265:
3255:
3245:
3215:
3210:
3180:
3160:
3044:
3039:
3014:
2979:
2964:
2939:
2922:
2912:
2870:
2841:
2806:
2772:
2689:
2679:
2659:
2623:
2608:
2603:
2573:
2507:
2503:
2485:
2433:
2412:
2372:
2367:
2306:
2237:
2212:
2187:
2110:
2045:
2005:
2000:
1980:
1975:
1955:
1945:
1935:
1850:
1830:
1812:
1720:
1391:
1197:
1107:
964:
746:
chemotherapy as a first line treatment for people with advanced CD20-positive
633:
520:
449:
349:
22:
5458:
5453:
5438:
5413:
5368:
5348:
5308:
5243:
5207:
5129:
4925:
4878:
4807:
4773:
4740:
4550:
4530:
4439:
4339:
4179:
3817:
3807:
3599:
3564:
3539:
3476:
3436:
3426:
3406:
3340:
3260:
3225:
3195:
3034:
3024:
3019:
2989:
2969:
2917:
2907:
2895:
2890:
2836:
2831:
2777:
2710:
2583:
2578:
2563:
2558:
2553:
2543:
2538:
2533:
2438:
2428:
2407:
2402:
2397:
2392:
2387:
2377:
2357:
2321:
2316:
2311:
2301:
2296:
2263:
2258:
2253:
2222:
2202:
2197:
2040:
2030:
1855:
1703:
998:"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions"
715:
640:; GA101 was one of its lead products when it was acquired by Roche in 2005.
587:
546:
102:
51:
1399:
1294:
1251:
1216:
1165:
1126:
1021:
982:
1013:
651:
but as of 2014 it appeared the development in that indication had halted.
5393:
5268:
4957:
4465:
4375:
4311:
4233:
3095:
2784:
2548:
2352:
2291:
2247:
2207:
2177:
1930:
1794:
1790:
1715:
1509:
329:
147:
703:
followed by obinutuzumab monotherapy for the treatment of patients with
338:
4886:
1888:
1243:
583:
63:
530:
followed by obinutuzumab monotherapy for the treatment of people with
5201:
5032:
742:
in people who had high expression of CD20; and in combination with
394:
4900:
4753:
2768:
2494:
2328:
2277:
1757:
606:
55:
1286:
767:
WHO Drug Information, Vol. 23, No. 2, 2009 Proposed INN: List 101
695:
In February 2016, obinutuzumab was approved by the FDA under the
134:
4872:
4820:
4781:
4767:
4321:
4195:
2883:
2669:
2167:
1893:
1875:
1865:
1825:
1693:
1316:
WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99
674:
493:
385:
270:
125:
68:
4056:
3059:
1628:
586:
on CD20 that partially overlaps with the epitope recognized by
255:
142:
4729:
1179:
Basu B, Angeletti A, Islam B, Ghiggeri GM (11 February 2022).
1089:
Basu B, Angeletti A, Islam B, Ghiggeri GM (11 February 2022).
815:
688:, the list price of obinutuzumab provided by the manufacturer
534:
as a second line treatment to a regimen containing rituximab.
707:
as a secondline treatment to a regimen containing rituximab.
617:, which in turn increases the antibody's ability to activate
511:
As of 2015, obinutuzumab was being used in combination with
1480:"NICE denies Roche cancer drug due to 'data uncertainties'"
242:
174:
790:"Australian Product Information - Gazyva® (obinutuzumab)"
593:
GlycArt's technology platform allowed control of protein
878:"Gazyva- obinutuzumab injection, solution, concentrate"
475:
1142:
Clinical Journal of the American Society of Nephrology
5494:
1373:
1371:
1369:
686:
Canadian Agency for Drugs and Technologies in Health
615:
reduce the amount of fucose attached to the antibody
5261:
5189:
5162:
5047:
4690:
4392:
4383:
4374:
4367:
4320:
4302:
4293:
4247:
4178:
4108:
4099:
3983:
3960:
3623:
3510:
3364:
3103:
3094:
2740:
2517:
2158:
2148:
1908:
1789:
1749:
1684:
1671:
1448:"F.D.A. Clears New Cancer-Fighting Drug From Roche"
448:
409:
404:
384:
364:
348:
328:
308:
303:
290:
282:
232:
227:
202:
188:
162:
115:
97:
89:
79:
74:
62:
45:
35:
28:
872:
870:
868:
866:
864:
862:
1363:by Dr. Joël Jean-Mairet. Brussels, March 31, 2011
718:in combination with obinutuzumab for people with
953:Journal of the Advanced Practitioner in Oncology
658:(FDA) approved obinutuzumab in combination with
905:
903:
634:Swiss Federal Institute of Technology in Zurich
537:Obinutuzumab was not tested in pregnant women.
317:
942:
940:
938:
936:
4068:
3071:
1640:
8:
1510:"NICE technology appraisal guidance (TA343)"
151:
21:
784:
782:
738:, as a monotherapy for relapsed/refractory
605:to overexpress two glycosylation enzymes,
4389:
4380:
4371:
4299:
4105:
4075:
4061:
4053:
3100:
3078:
3064:
3056:
2155:
1681:
1647:
1633:
1625:
1054:
1052:
555:progressive multifocal leukoencephalopathy
1206:
1196:
1116:
1106:
972:
373:
1424:(Press release). FDA. 13 November 2013.
5501:
759:
750:. It was called GA101 during research.
726:who have not received prior treatment.
565:Obinutuzumab in difficult nephropathies
337:
1034:
841:Therapeutic Goods Administration (TGA)
20:
1456:. Associated Press. 2 November 2013.
597:; the cells in which obinutuzumab is
582:monoclonal antibody that binds to an
107:
7:
5527:Drugs developed by Hoffmann-La Roche
1552:from the original on 18 October 2015
888:from the original on 24 January 2021
699:program for use in combination with
526:It is also used in combination with
215:
1490:from the original on 6 October 2014
1460:from the original on 6 October 2021
1428:from the original on 21 August 2015
647:to explore the use of the drug for
393:
1578:from the original on 4 August 2020
1516:from the original on 15 March 2016
1070:from the original on 27 March 2023
1041:: CS1 maint: overridden setting (
847:from the original on 10 April 2023
638:afucosylated monoclonal antibodies
492:among others, is a humanized anti-
14:
1064:U.S. Food and Drug Administration
921:from the original on 2 March 2021
5537:Monoclonal antibodies for tumors
5504:
427:
421:
1606:NCI Dictionary of Cancer Terms
947:Evans SS, Clemmons AB (2015).
670:designation to gain approval.
666:, and was the first drug with
662:as a first-line treatment for
515:as a first-line treatment for
439:
433:
415:
1:
748:diffuse large B-cell lymphoma
5532:Drugs developed by Genentech
4140:dihydroorotate dehydrogenase
1608:. National Cancer Institute.
1154:10.2215/cjn.0000000000000288
736:chronic lymphocytic leukemia
720:chronic lymphocytic leukemia
712:Food and Drug Administration
664:chronic lymphocytic leukemia
656:Food and Drug Administration
517:chronic lymphocytic leukemia
488:, sold under the brand name
4119:purine synthesis inhibitors
1338:. roche.com. Archived from
5558:
2150:Tyrosine kinase inhibitors
724:small lymphocytic lymphoma
405:Chemical and physical data
4304:IL-1 receptor antagonists
4013:
3595:Mirvetuximab soravtansine
2016:Mirvetuximab soravtansine
1618:National Cancer Institute
1392:10.1007/s40265-013-0167-3
1198:10.3389/fimmu.2022.805697
1108:10.3389/fimmu.2022.805697
965:10.6004/jadpro.2015.6.4.7
915:European Medicines Agency
654:In November 2013, the US
649:primary biliary cirrhosis
465:
5177:Anti-lymphocyte globulin
2160:Receptor tyrosine kinase
1686:Receptor tyrosine kinase
710:In January 2019, the US
5172:Anti-thymocyte globulin
4084:Immunosuppressive drugs
3991:Depatuxizumab mafodotin
3932:Tucotuzumab celmoleukin
3883:Rovalpituzumab tesirine
3798:Lorvotuzumab mertansine
3688:Clivatuzumab tetraxetan
1750:Others for solid tumors
1656:Targeted cancer therapy
1321:25 October 2021 at the
1185:Frontiers in Immunology
1095:Frontiers in Immunology
4977:Interleukin-6 receptor
4403:Complement component 5
3952:Vorsetuzumab mafodotin
3908:Tacatuzumab tetraxetan
3713:Denintuzumab mafodotin
3658:Bivatuzumab mertansine
3585:Loncastuximab tesirine
3575:Indatuximab ravtansine
3452:Naptumomab estafenatox
2011:Loncastuximab tesirine
1740:Trastuzumab deruxtecan
3937:Vandortuzumab vedotin
3888:Sacituzumab govitecan
3778:Inotuzumab ozogamicin
3763:Gemtuzumab ozogamicin
3693:Cofetuzumab pelidotin
3673:Cantuzumab ravtansine
3668:Cantuzumab mertansine
3487:Nofetumomab merpentan
3447:Moxetumomab pasudotox
3201:Glembatumumab vedotin
3087:Monoclonal antibodies
2086:Sacituzumab govitecan
2026:Moxetumomab pasudotox
1996:Inotuzumab ozogamicin
1899:Gemtuzumab ozogamicin
1735:Trastuzumab emtansine
1676:monoclonal antibodies
1660:antineoplastic agents
1014:10.1056/NEJMoa1815281
545:Obinutuzumab has two
3984:Chimeric + humanized
3788:Lifastuzumab vedotin
3648:Belantamab mafodotin
3417:Ibritumomab tiuxetan
3382:Anatumomab mafenatox
1941:Belantamab mafodotin
1275:Nature Biotechnology
1232:Nature Biotechnology
1066:. 26 February 2016.
772:3 March 2016 at the
740:non-Hodgkin lymphoma
668:breakthrough therapy
619:natural killer cells
197:Intravenous infusion
3903:Sofituzumab vedotin
3873:Polatuzumab vedotin
3868:Pinatuzumab vedotin
3853:Oportuzumab monatox
3683:Citatuzumab bogatox
3545:Derlotuximab biotin
3530:Brentuximab vedotin
3482:Taplitumomab paptox
3472:Satumomab pendetide
3442:Nacolomab tafenatox
3377:Altumomab pentetate
2794:Denileukin diftitox
2456:(ALK, ROS1, NTRK),
2061:Polatuzumab vedotin
2051:Oportuzumab monatox
1620:. 12 November 2013.
1545:. 27 January 2015.
705:follicular lymphoma
532:follicular lymphoma
497:monoclonal antibody
251:(Prescription only)
30:Monoclonal antibody
25:
5334:Diroximel fumarate
5007:IL-2 receptor/CD25
4435:Certolizumab pegol
4088:Immunosuppressants
4040:Never to phase III
3402:Capromab pendetide
3176:Enfortumab vedotin
2480:(ROS1, TRK, ALK),
1986:Enfortumab vedotin
1486:. 3 October 2014.
1453:The New York Times
1342:on 5 February 2015
1244:10.1038/nbt0114-6b
917:. 5 October 2023.
796:on 8 January 2023.
578:Obinutuzumab is a
5492:
5491:
5339:Efgartigimod alfa
5329:Dimethyl fumarate
5257:
5256:
5185:
5184:
5158:
5157:
4363:
4362:
4289:
4288:
4130:Mycophenolic acid
4050:
4049:
4009:
4008:
3331:Tisotumab vedotin
3053:
3052:
2736:
2735:
2144:
2143:
2126:Tisotumab vedotin
1148:(12): 1555–1562.
1008:(23): 2225–2236.
690:Hoffmann-La Roche
673:In October 2014,
553:reactivation and
483:
482:
274:
259:
246:
178:
145:
128:
93:afutuzumab, GA101
5549:
5509:
5508:
5507:
5500:
5135:Telimomab aritox
5038:Zolimomab aritox
4859:CD62L/L-selectin
4597:Immunoglobulin E
4390:
4381:
4372:
4300:
4106:
4077:
4070:
4063:
4054:
3962:Rat/mouse hybrid
3101:
3080:
3073:
3066:
3057:
2767:peptide against
2340:(AXL, ALK, LTK))
2156:
1966:Dinutuximab beta
1682:
1649:
1642:
1635:
1626:
1621:
1609:
1588:
1587:
1585:
1583:
1568:
1562:
1561:
1559:
1557:
1551:
1540:
1532:
1526:
1525:
1523:
1521:
1506:
1500:
1499:
1497:
1495:
1476:
1470:
1469:
1467:
1465:
1444:
1438:
1437:
1435:
1433:
1418:
1412:
1411:
1375:
1364:
1358:
1352:
1351:
1349:
1347:
1332:
1326:
1313:
1307:
1306:
1270:
1264:
1263:
1227:
1221:
1220:
1210:
1200:
1176:
1170:
1169:
1160: 10723910.
1137:
1131:
1130:
1120:
1110:
1086:
1080:
1079:
1077:
1075:
1056:
1047:
1046:
1040:
1032:
1030:
1028:
993:
987:
986:
976:
944:
931:
930:
928:
926:
907:
898:
897:
895:
893:
884:. 7 April 2020.
874:
857:
856:
854:
852:
843:. 21 June 2022.
833:
827:
826:
824:
822:
812:nctr-crs.fda.gov
804:
798:
797:
792:. Archived from
786:
777:
764:
479:
478:
471:
460:
458:
441:
435:
429:
423:
417:
397:
377:
341:
321:
295:
272:
269:
264:
257:
254:
244:
241:
219:
176:
173:
155:
144:
141:
138:
127:
124:
111:
85:Gazyva, Gazyvaro
26:
24:
5557:
5556:
5552:
5551:
5550:
5548:
5547:
5546:
5517:
5516:
5515:
5505:
5503:
5495:
5493:
5488:
5434:Rozanolixizumab
5319:Deucravacitinib
5253:
5181:
5154:
5043:
4692:
4686:
4394:
4359:
4316:
4295:
4285:
4243:
4183:
4174:
4110:Antimetabolites
4101:
4095:
4081:
4051:
4046:
4045:
4030:Clinical trials
4005:
3979:
3956:
3619:
3506:
3360:
3090:
3084:
3054:
3049:
2903:Pi3K inhibitors
2801:mTOR inhibitors
2732:
2513:
2484:(VEGFR, FGFR),
2140:
1904:
1785:
1745:
1667:
1653:
1612:
1600:
1597:
1592:
1591:
1581:
1579:
1570:
1569:
1565:
1555:
1553:
1549:
1538:
1534:
1533:
1529:
1519:
1517:
1512:. 2 June 2015.
1508:
1507:
1503:
1493:
1491:
1478:
1477:
1473:
1463:
1461:
1446:
1445:
1441:
1431:
1429:
1420:
1419:
1415:
1377:
1376:
1367:
1359:
1355:
1345:
1343:
1334:
1333:
1329:
1323:Wayback Machine
1314:
1310:
1272:
1271:
1267:
1229:
1228:
1224:
1178:
1177:
1173:
1139:
1138:
1134:
1088:
1087:
1083:
1073:
1071:
1058:
1057:
1050:
1033:
1026:
1024:
995:
994:
990:
946:
945:
934:
924:
922:
911:"Gazyvaro EPAR"
909:
908:
901:
891:
889:
876:
875:
860:
850:
848:
835:
834:
830:
820:
818:
806:
805:
801:
788:
787:
780:
774:Wayback Machine
765:
761:
756:
732:
714:(FDA) approved
697:Priority Review
677:announced that
630:
580:fully humanized
576:
567:
543:
509:
474:
472:
469:(what is this?)
466:
456:
454:
444:
438:
432:
426:
420:
400:
380:
360:
344:
324:
293:
284:Pharmacokinetic
278:
262:
223:
191:
184:
165:
158:
17:
12:
11:
5:
5555:
5553:
5545:
5544:
5539:
5534:
5529:
5519:
5518:
5514:
5513:
5490:
5489:
5487:
5486:
5481:
5476:
5471:
5466:
5461:
5456:
5451:
5446:
5441:
5436:
5431:
5426:
5421:
5416:
5411:
5406:
5401:
5396:
5391:
5386:
5381:
5376:
5371:
5366:
5361:
5356:
5351:
5346:
5343:+hyaluronidase
5336:
5331:
5326:
5324:Deuruxolitinib
5321:
5316:
5311:
5306:
5301:
5296:
5291:
5286:
5281:
5276:
5271:
5265:
5263:
5259:
5258:
5255:
5254:
5252:
5251:
5246:
5241:
5236:
5235:
5234:
5229:
5217:
5216:
5215:
5210:
5197:
5195:
5187:
5186:
5183:
5182:
5180:
5179:
5174:
5168:
5166:
5160:
5159:
5156:
5155:
5153:
5152:
5147:
5142:
5137:
5132:
5127:
5122:
5117:
5112:
5107:
5102:
5097:
5092:
5087:
5082:
5077:
5072:
5067:
5062:
5057:
5051:
5049:
5045:
5044:
5042:
5041:
5028:
5027:
5026:
5025:
5020:
5015:
5002:
5001:
5000:
4999:
4987:
4986:
4985:
4973:
4972:
4971:
4966:
4954:
4953:
4952:
4947:
4942:
4930:
4929:
4928:
4917:
4916:
4915:
4914:
4909:
4897:
4896:
4895:
4883:
4882:
4881:
4869:
4868:
4867:
4855:
4854:
4853:
4848:
4836:
4835:
4834:
4829:
4817:
4816:
4815:
4810:
4805:
4800:
4797:+hyaluronidase
4790:
4778:
4777:
4776:
4764:
4763:
4762:
4750:
4749:
4748:
4743:
4738:
4726:
4725:
4724:
4719:
4714:
4709:
4696:
4694:
4688:
4687:
4685:
4684:
4683:
4682:
4669:
4668:
4667:
4666:
4661:
4640:
4639:
4638:
4637:
4624:
4623:
4622:
4621:
4608:
4607:
4606:
4605:
4592:
4591:
4590:
4589:
4576:
4575:
4574:
4573:
4568:
4563:
4558:
4553:
4548:
4543:
4538:
4533:
4528:
4523:
4518:
4513:
4508:
4503:
4498:
4493:
4488:
4483:
4478:
4473:
4468:
4455:
4454:
4453:
4452:
4447:
4442:
4437:
4432:
4427:
4414:
4413:
4412:
4411:
4398:
4396:
4387:
4378:
4369:
4365:
4364:
4361:
4360:
4358:
4357:
4352:
4347:
4342:
4337:
4332:
4326:
4324:
4318:
4317:
4315:
4314:
4308:
4306:
4297:
4291:
4290:
4287:
4286:
4284:
4283:
4282:
4281:
4273:PDE4 inhibitor
4269:
4264:
4259:
4253:
4251:
4245:
4244:
4242:
4241:
4236:
4230:
4229:
4228:
4227:
4222:
4217:
4212:
4191:
4189:
4176:
4175:
4173:
4172:
4171:
4170:
4157:
4156:
4155:
4154:
4149:
4135:
4134:
4133:
4132:
4127:
4114:
4112:
4103:
4097:
4096:
4082:
4080:
4079:
4072:
4065:
4057:
4048:
4047:
4044:
4043:
4042:
4041:
4038:
4027:
4021:
4015:
4014:
4011:
4010:
4007:
4006:
4004:
4003:
3998:
3996:Duvortuxizumab
3993:
3987:
3985:
3981:
3980:
3978:
3977:
3972:
3966:
3964:
3958:
3957:
3955:
3954:
3949:
3944:
3939:
3934:
3929:
3915:
3910:
3905:
3900:
3895:
3890:
3885:
3880:
3875:
3870:
3865:
3860:
3855:
3850:
3845:
3840:
3835:
3830:
3825:
3820:
3815:
3810:
3805:
3800:
3795:
3790:
3785:
3780:
3775:
3770:
3765:
3760:
3755:
3750:
3745:
3740:
3735:
3730:
3725:
3720:
3715:
3710:
3705:
3700:
3695:
3690:
3685:
3680:
3675:
3670:
3665:
3663:Brontictuzumab
3660:
3655:
3650:
3645:
3640:
3635:
3629:
3627:
3621:
3620:
3618:
3617:
3612:
3607:
3602:
3597:
3592:
3587:
3582:
3577:
3572:
3567:
3562:
3557:
3552:
3547:
3542:
3537:
3532:
3527:
3522:
3516:
3514:
3508:
3507:
3505:
3504:
3499:
3494:
3489:
3484:
3479:
3474:
3469:
3464:
3459:
3454:
3449:
3444:
3439:
3434:
3429:
3424:
3419:
3414:
3409:
3404:
3399:
3394:
3389:
3384:
3379:
3374:
3368:
3366:
3362:
3361:
3359:
3358:
3353:
3348:
3343:
3338:
3333:
3328:
3323:
3318:
3313:
3308:
3303:
3298:
3293:
3288:
3283:
3278:
3273:
3268:
3263:
3258:
3253:
3248:
3243:
3238:
3233:
3228:
3223:
3218:
3213:
3208:
3203:
3198:
3193:
3188:
3183:
3178:
3173:
3168:
3163:
3158:
3153:
3148:
3143:
3138:
3133:
3130:+hyaluronidase
3123:
3118:
3113:
3107:
3105:
3098:
3092:
3091:
3085:
3083:
3082:
3075:
3068:
3060:
3051:
3050:
3048:
3047:
3042:
3037:
3032:
3027:
3022:
3017:
3012:
3007:
3002:
2997:
2992:
2987:
2982:
2977:
2972:
2967:
2962:
2957:
2952:
2947:
2942:
2937:
2932:
2931:
2930:
2925:
2920:
2915:
2910:
2900:
2899:
2898:
2893:
2880:
2879:
2878:
2873:
2868:
2863:
2858:
2850:CDK inhibitors
2846:
2845:
2844:
2839:
2834:
2821:
2820:
2819:
2814:
2809:
2797:
2781:
2761:
2749:fusion protein
2744:
2742:
2738:
2737:
2734:
2733:
2731:
2730:
2729:
2728:
2723:
2718:
2713:
2708:
2695:
2694:
2693:
2692:
2687:
2682:
2665:
2664:
2663:
2662:
2657:
2652:
2647:
2634:
2633:
2632:
2631:
2626:
2621:
2616:
2611:
2606:
2601:
2588:
2587:
2581:
2569:
2568:
2567:
2566:
2561:
2556:
2551:
2546:
2541:
2536:
2523:
2521:
2515:
2514:
2512:
2511:
2490:
2489:
2488:(VEGFR, EGFR).
2444:
2443:
2442:
2441:
2436:
2431:
2418:
2417:
2416:
2415:
2410:
2405:
2400:
2395:
2390:
2385:
2380:
2375:
2370:
2365:
2360:
2355:
2342:
2341:
2325:
2319:
2314:
2309:
2304:
2299:
2294:
2289:
2269:
2268:
2267:
2266:
2261:
2256:
2246:HER1/EGFR and
2242:
2241:
2235:
2230:
2225:
2220:
2215:
2210:
2205:
2200:
2195:
2190:
2185:
2180:
2164:
2162:
2153:
2146:
2145:
2142:
2141:
2139:
2138:
2133:
2128:
2123:
2118:
2113:
2108:
2103:
2098:
2093:
2088:
2083:
2078:
2073:
2068:
2063:
2058:
2053:
2048:
2043:
2038:
2033:
2028:
2023:
2018:
2013:
2008:
2003:
1998:
1993:
1988:
1983:
1978:
1973:
1968:
1963:
1958:
1953:
1948:
1943:
1938:
1933:
1928:
1925:+hyaluronidase
1918:
1912:
1910:
1906:
1905:
1903:
1902:
1885:
1884:
1858:
1853:
1848:
1843:
1838:
1833:
1799:
1797:
1787:
1786:
1784:
1783:
1771:
1765:
1753:
1751:
1747:
1746:
1744:
1743:
1737:
1732:
1729:+hyaluronidase
1712:
1706:
1690:
1688:
1679:
1669:
1668:
1654:
1652:
1651:
1644:
1637:
1629:
1623:
1622:
1614:"Obinutuzumab"
1610:
1602:"Obinutuzumab"
1596:
1595:External links
1593:
1590:
1589:
1563:
1527:
1501:
1471:
1439:
1413:
1365:
1353:
1327:
1308:
1265:
1222:
1171:
1132:
1081:
1060:"Obinutuzumab"
1048:
988:
932:
899:
858:
828:
799:
778:
758:
757:
755:
752:
731:
728:
629:
626:
575:
572:
566:
563:
542:
539:
508:
505:
481:
480:
463:
462:
452:
446:
445:
442:
436:
430:
424:
418:
413:
407:
406:
402:
401:
399:
398:
390:
388:
382:
381:
379:
378:
370:
368:
362:
361:
359:
358:
354:
352:
346:
345:
343:
342:
334:
332:
326:
325:
323:
322:
314:
312:
306:
305:
301:
300:
297:
288:
287:
280:
279:
277:
276:
267:
252:
238:
236:
230:
229:
225:
224:
222:
221:
208:
206:
200:
199:
194:
192:administration
186:
185:
183:
182:
180:
170:
168:
160:
159:
157:
156:
139:
121:
119:
113:
112:
105:
95:
94:
91:
87:
86:
83:
77:
76:
72:
71:
66:
60:
59:
49:
43:
42:
41:Whole antibody
39:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
5554:
5543:
5540:
5538:
5535:
5533:
5530:
5528:
5525:
5524:
5522:
5512:
5502:
5498:
5485:
5482:
5480:
5477:
5475:
5474:Tildrakizumab
5472:
5470:
5467:
5465:
5462:
5460:
5457:
5455:
5452:
5450:
5447:
5445:
5442:
5440:
5437:
5435:
5432:
5430:
5427:
5425:
5422:
5420:
5417:
5415:
5412:
5410:
5407:
5405:
5404:Pegcetacoplan
5402:
5400:
5397:
5395:
5392:
5390:
5387:
5385:
5382:
5380:
5377:
5375:
5372:
5370:
5367:
5365:
5362:
5360:
5357:
5355:
5352:
5350:
5347:
5344:
5340:
5337:
5335:
5332:
5330:
5327:
5325:
5322:
5320:
5317:
5315:
5314:Darvadstrocel
5312:
5310:
5307:
5305:
5302:
5300:
5297:
5295:
5292:
5290:
5287:
5285:
5282:
5280:
5277:
5275:
5272:
5270:
5267:
5266:
5264:
5260:
5250:
5247:
5245:
5242:
5240:
5237:
5233:
5230:
5228:
5225:
5224:
5223:
5222:
5221:TNF inhibitor
5218:
5214:
5211:
5209:
5206:
5205:
5204:
5203:
5199:
5198:
5196:
5193:
5188:
5178:
5175:
5173:
5170:
5169:
5167:
5165:
5161:
5151:
5148:
5146:
5143:
5141:
5138:
5136:
5133:
5131:
5128:
5126:
5123:
5121:
5118:
5116:
5113:
5111:
5108:
5106:
5103:
5101:
5098:
5096:
5093:
5091:
5088:
5086:
5083:
5081:
5078:
5076:
5073:
5071:
5068:
5066:
5063:
5061:
5058:
5056:
5053:
5052:
5050:
5046:
5039:
5035:
5034:
5030:
5029:
5024:
5021:
5019:
5016:
5014:
5011:
5010:
5009:
5008:
5004:
5003:
4998:
4995:
4994:
4993:
4992:
4988:
4984:
4981:
4980:
4979:
4978:
4974:
4970:
4967:
4965:
4962:
4961:
4960:
4959:
4955:
4951:
4948:
4946:
4943:
4941:
4938:
4937:
4936:
4935:
4931:
4927:
4924:
4923:
4922:
4919:
4918:
4913:
4910:
4908:
4905:
4904:
4903:
4902:
4898:
4894:
4891:
4890:
4889:
4888:
4887:CD147/Basigin
4884:
4880:
4877:
4876:
4875:
4874:
4870:
4866:
4863:
4862:
4861:
4860:
4856:
4852:
4849:
4847:
4844:
4843:
4842:
4841:
4837:
4833:
4830:
4828:
4825:
4824:
4823:
4822:
4818:
4814:
4811:
4809:
4806:
4804:
4801:
4798:
4794:
4791:
4789:
4786:
4785:
4784:
4783:
4779:
4775:
4772:
4771:
4770:
4769:
4765:
4761:
4758:
4757:
4756:
4755:
4751:
4747:
4744:
4742:
4739:
4737:
4734:
4733:
4732:
4731:
4727:
4723:
4720:
4718:
4715:
4713:
4710:
4708:
4707:Muromonab-CD3
4705:
4704:
4703:
4702:
4698:
4697:
4695:
4689:
4681:
4678:
4677:
4676:
4675:
4671:
4670:
4665:
4662:
4660:
4657:
4656:
4655:
4654:
4650:
4646:
4642:
4641:
4636:
4633:
4632:
4631:
4630:
4626:
4625:
4620:
4617:
4616:
4615:
4614:
4610:
4609:
4604:
4601:
4600:
4599:
4598:
4594:
4593:
4588:
4585:
4584:
4583:
4582:
4581:Interleukin 5
4578:
4577:
4572:
4569:
4567:
4564:
4562:
4561:Tildrakizumab
4559:
4557:
4554:
4552:
4549:
4547:
4544:
4542:
4539:
4537:
4534:
4532:
4529:
4527:
4524:
4522:
4519:
4517:
4514:
4512:
4509:
4507:
4504:
4502:
4499:
4497:
4494:
4492:
4489:
4487:
4484:
4482:
4479:
4477:
4474:
4472:
4469:
4467:
4464:
4463:
4462:
4461:
4457:
4456:
4451:
4448:
4446:
4443:
4441:
4438:
4436:
4433:
4431:
4428:
4426:
4423:
4422:
4421:
4420:
4416:
4415:
4410:
4407:
4406:
4405:
4404:
4400:
4399:
4397:
4395:(noncellular)
4391:
4388:
4386:
4382:
4379:
4377:
4373:
4370:
4368:Extracellular
4366:
4356:
4353:
4351:
4348:
4346:
4343:
4341:
4338:
4336:
4335:Ridaforolimus
4333:
4331:
4328:
4327:
4325:
4323:
4319:
4313:
4310:
4309:
4307:
4305:
4301:
4298:
4294:Intracellular
4292:
4280:
4277:
4276:
4275:
4274:
4270:
4268:
4265:
4263:
4260:
4258:
4255:
4254:
4252:
4250:
4246:
4240:
4237:
4235:
4232:
4231:
4226:
4223:
4221:
4218:
4216:
4213:
4211:
4208:
4207:
4206:
4205:
4201:
4197:
4193:
4192:
4190:
4187:
4181:
4177:
4169:
4166:
4165:
4164:
4163:
4159:
4158:
4153:
4152:Teriflunomide
4150:
4148:
4145:
4144:
4142:
4141:
4137:
4136:
4131:
4128:
4126:
4123:
4122:
4121:
4120:
4116:
4115:
4113:
4111:
4107:
4104:
4100:Intracellular
4098:
4093:
4089:
4085:
4078:
4073:
4071:
4066:
4064:
4059:
4058:
4055:
4039:
4037:
4034:
4033:
4031:
4028:
4025:
4022:
4020:
4017:
4016:
4012:
4002:
3999:
3997:
3994:
3992:
3989:
3988:
3986:
3982:
3976:
3973:
3971:
3968:
3967:
3965:
3963:
3959:
3953:
3950:
3948:
3945:
3943:
3940:
3938:
3935:
3933:
3930:
3927:
3923:
3919:
3916:
3914:
3911:
3909:
3906:
3904:
3901:
3899:
3896:
3894:
3891:
3889:
3886:
3884:
3881:
3879:
3878:Rosmantuzumab
3876:
3874:
3871:
3869:
3866:
3864:
3861:
3859:
3856:
3854:
3851:
3849:
3846:
3844:
3841:
3839:
3836:
3834:
3831:
3829:
3826:
3824:
3821:
3819:
3816:
3814:
3811:
3809:
3806:
3804:
3801:
3799:
3796:
3794:
3791:
3789:
3786:
3784:
3781:
3779:
3776:
3774:
3771:
3769:
3766:
3764:
3761:
3759:
3756:
3754:
3751:
3749:
3746:
3744:
3741:
3739:
3736:
3734:
3733:Enoblituzumab
3731:
3729:
3726:
3724:
3721:
3719:
3716:
3714:
3711:
3709:
3706:
3704:
3701:
3699:
3696:
3694:
3691:
3689:
3686:
3684:
3681:
3679:
3676:
3674:
3671:
3669:
3666:
3664:
3661:
3659:
3656:
3654:
3651:
3649:
3646:
3644:
3641:
3639:
3636:
3634:
3631:
3630:
3628:
3626:
3622:
3616:
3613:
3611:
3608:
3606:
3603:
3601:
3598:
3596:
3593:
3591:
3588:
3586:
3583:
3581:
3578:
3576:
3573:
3571:
3568:
3566:
3563:
3561:
3558:
3556:
3553:
3551:
3548:
3546:
3543:
3541:
3538:
3536:
3533:
3531:
3528:
3526:
3523:
3521:
3518:
3517:
3515:
3513:
3509:
3503:
3500:
3498:
3495:
3493:
3490:
3488:
3485:
3483:
3480:
3478:
3475:
3473:
3470:
3468:
3465:
3463:
3460:
3458:
3455:
3453:
3450:
3448:
3445:
3443:
3440:
3438:
3435:
3433:
3430:
3428:
3425:
3423:
3420:
3418:
3415:
3413:
3410:
3408:
3405:
3403:
3400:
3398:
3395:
3393:
3390:
3388:
3385:
3383:
3380:
3378:
3375:
3373:
3370:
3369:
3367:
3363:
3357:
3354:
3352:
3349:
3347:
3344:
3342:
3339:
3337:
3334:
3332:
3329:
3327:
3324:
3322:
3319:
3317:
3314:
3312:
3309:
3307:
3304:
3302:
3299:
3297:
3294:
3292:
3289:
3287:
3286:Pembrolizumab
3284:
3282:
3279:
3277:
3274:
3272:
3269:
3267:
3264:
3262:
3259:
3257:
3254:
3252:
3249:
3247:
3244:
3242:
3239:
3237:
3234:
3232:
3229:
3227:
3224:
3222:
3219:
3217:
3214:
3212:
3209:
3207:
3204:
3202:
3199:
3197:
3194:
3192:
3189:
3187:
3184:
3182:
3179:
3177:
3174:
3172:
3169:
3167:
3164:
3162:
3159:
3157:
3154:
3152:
3149:
3147:
3144:
3142:
3139:
3137:
3134:
3131:
3127:
3124:
3122:
3121:Ascrinvacumab
3119:
3117:
3114:
3112:
3109:
3108:
3106:
3102:
3099:
3097:
3093:
3088:
3081:
3076:
3074:
3069:
3067:
3062:
3061:
3058:
3046:
3043:
3041:
3038:
3036:
3033:
3031:
3028:
3026:
3023:
3021:
3018:
3016:
3013:
3011:
3008:
3006:
3003:
3001:
2998:
2996:
2993:
2991:
2988:
2986:
2983:
2981:
2978:
2976:
2973:
2971:
2968:
2966:
2963:
2961:
2960:Larotrectinib
2958:
2956:
2953:
2951:
2948:
2946:
2943:
2941:
2938:
2936:
2933:
2929:
2926:
2924:
2921:
2919:
2916:
2914:
2911:
2909:
2906:
2905:
2904:
2901:
2897:
2894:
2892:
2889:
2888:
2887:
2885:
2881:
2877:
2874:
2872:
2869:
2867:
2864:
2862:
2859:
2857:
2854:
2853:
2852:
2851:
2847:
2843:
2840:
2838:
2835:
2833:
2830:
2829:
2828:
2826:
2822:
2818:
2815:
2813:
2812:Ridaforolimus
2810:
2808:
2805:
2804:
2803:
2802:
2798:
2795:
2791:
2790:
2786:
2782:
2779:
2775:
2774:
2770:
2766:
2762:
2759:
2755:
2754:
2750:
2746:
2745:
2743:
2739:
2727:
2724:
2722:
2721:Pirtobrutinib
2719:
2717:
2716:Orelabrutinib
2714:
2712:
2709:
2707:
2706:Acalabrutinib
2704:
2703:
2702:
2701:
2697:
2696:
2691:
2688:
2686:
2683:
2681:
2678:
2677:
2676:
2675:
2671:
2667:
2666:
2661:
2658:
2656:
2653:
2651:
2648:
2646:
2643:
2642:
2641:
2640:
2636:
2635:
2630:
2627:
2625:
2622:
2620:
2617:
2615:
2612:
2610:
2607:
2605:
2602:
2600:
2597:
2596:
2595:
2594:
2590:
2589:
2585:
2582:
2580:
2576:
2575:
2571:
2570:
2565:
2562:
2560:
2557:
2555:
2552:
2550:
2547:
2545:
2542:
2540:
2537:
2535:
2532:
2531:
2530:
2529:
2525:
2524:
2522:
2520:
2516:
2509:
2505:
2501:
2498:
2496:
2492:
2491:
2487:
2483:
2482:Selpercatinib
2479:
2478:Repotrectinib
2475:
2471:
2467:
2466:Larotrectinib
2463:
2459:
2455:
2452:
2450:
2446:
2445:
2440:
2437:
2435:
2432:
2430:
2427:
2426:
2425:
2424:
2420:
2419:
2414:
2411:
2409:
2406:
2404:
2401:
2399:
2396:
2394:
2391:
2389:
2386:
2384:
2381:
2379:
2376:
2374:
2371:
2369:
2366:
2364:
2361:
2359:
2356:
2354:
2351:
2350:
2349:
2348:
2344:
2343:
2339:
2335:
2331:
2330:
2326:
2323:
2320:
2318:
2315:
2313:
2310:
2308:
2305:
2303:
2300:
2298:
2295:
2293:
2290:
2288:
2284:
2283:
2279:
2274:
2273:RTK class III
2271:
2270:
2265:
2262:
2260:
2257:
2255:
2252:
2251:
2250:
2249:
2244:
2243:
2239:
2236:
2234:
2231:
2229:
2226:
2224:
2221:
2219:
2216:
2214:
2211:
2209:
2206:
2204:
2201:
2199:
2196:
2194:
2191:
2189:
2186:
2184:
2181:
2179:
2175:
2174:
2169:
2166:
2165:
2163:
2161:
2157:
2154:
2151:
2147:
2137:
2134:
2132:
2129:
2127:
2124:
2122:
2119:
2117:
2114:
2112:
2109:
2107:
2104:
2102:
2099:
2097:
2094:
2092:
2089:
2087:
2084:
2082:
2079:
2077:
2074:
2072:
2069:
2067:
2064:
2062:
2059:
2057:
2056:Pembrolizumab
2054:
2052:
2049:
2047:
2044:
2042:
2039:
2037:
2034:
2032:
2029:
2027:
2024:
2022:
2021:Mogamulizumab
2019:
2017:
2014:
2012:
2009:
2007:
2004:
2002:
1999:
1997:
1994:
1992:
1989:
1987:
1984:
1982:
1979:
1977:
1974:
1972:
1969:
1967:
1964:
1962:
1959:
1957:
1954:
1952:
1949:
1947:
1944:
1942:
1939:
1937:
1934:
1932:
1929:
1926:
1922:
1919:
1917:
1914:
1913:
1911:
1907:
1900:
1896:
1895:
1890:
1887:
1886:
1882:
1878:
1877:
1872:
1868:
1867:
1862:
1859:
1857:
1854:
1852:
1849:
1847:
1844:
1842:
1841:Mosunetuzumab
1839:
1837:
1834:
1832:
1828:
1827:
1822:
1821:Mosunetuzumab
1818:
1814:
1810:
1809:
1804:
1801:
1800:
1798:
1796:
1792:
1788:
1781:
1777:
1776:
1772:
1769:
1766:
1764:
1760:
1759:
1755:
1754:
1752:
1748:
1741:
1738:
1736:
1733:
1730:
1726:
1722:
1718:
1717:
1713:
1710:
1707:
1705:
1701:
1700:
1695:
1692:
1691:
1689:
1687:
1683:
1680:
1677:
1674:
1670:
1665:
1661:
1657:
1650:
1645:
1643:
1638:
1636:
1631:
1630:
1627:
1619:
1615:
1611:
1607:
1603:
1599:
1598:
1594:
1577:
1573:
1567:
1564:
1548:
1544:
1537:
1531:
1528:
1515:
1511:
1505:
1502:
1489:
1485:
1481:
1475:
1472:
1459:
1455:
1454:
1449:
1443:
1440:
1427:
1423:
1417:
1414:
1409:
1405:
1401:
1397:
1393:
1389:
1386:(1): 147–54.
1385:
1381:
1374:
1372:
1370:
1366:
1362:
1357:
1354:
1341:
1337:
1331:
1328:
1324:
1320:
1317:
1312:
1309:
1304:
1300:
1296:
1292:
1288:
1284:
1281:(2): 176–80.
1280:
1276:
1269:
1266:
1261:
1257:
1253:
1249:
1245:
1241:
1237:
1233:
1226:
1223:
1218:
1214:
1209:
1204:
1199:
1194:
1190:
1186:
1182:
1175:
1172:
1167:
1163:
1159:
1155:
1151:
1147:
1143:
1136:
1133:
1128:
1124:
1119:
1114:
1109:
1104:
1100:
1096:
1092:
1085:
1082:
1069:
1065:
1061:
1055:
1053:
1049:
1044:
1038:
1023:
1019:
1015:
1011:
1007:
1003:
999:
992:
989:
984:
980:
975:
970:
966:
962:
958:
954:
950:
943:
941:
939:
937:
933:
920:
916:
912:
906:
904:
900:
887:
883:
879:
873:
871:
869:
867:
865:
863:
859:
846:
842:
838:
832:
829:
817:
813:
809:
803:
800:
795:
791:
785:
783:
779:
775:
771:
768:
763:
760:
753:
751:
749:
745:
741:
737:
729:
727:
725:
721:
717:
713:
708:
706:
702:
698:
693:
691:
687:
682:
680:
676:
671:
669:
665:
661:
657:
652:
650:
646:
641:
639:
635:
627:
625:
622:
620:
616:
612:
608:
604:
600:
596:
595:glycosylation
591:
589:
585:
581:
573:
571:
564:
562:
558:
556:
552:
548:
540:
538:
535:
533:
529:
524:
522:
518:
514:
506:
504:
502:
498:
495:
491:
487:
477:
470:
464:
453:
451:
447:
414:
412:
408:
403:
396:
392:
391:
389:
387:
383:
376:
372:
371:
369:
367:
363:
356:
355:
353:
351:
347:
340:
336:
335:
333:
331:
327:
320:
316:
315:
313:
311:
307:
302:
298:
296:
289:
285:
281:
275: Rx-only
268:
265:
253:
250:
240:
239:
237:
235:
231:
226:
218:
213:
210:
209:
207:
205:
201:
198:
195:
193:
187:
181:
172:
171:
169:
167:
161:
154:
149:
140:
137:
132:
123:
122:
120:
118:
114:
110:
106:
104:
100:
96:
92:
88:
84:
82:
78:
75:Clinical data
73:
70:
67:
65:
61:
57:
53:
50:
48:
44:
40:
38:
34:
31:
27:
19:
5542:Orphan drugs
5484:Upadacitinib
5444:Satralizumab
5429:Ritlecitinib
5424:Risankizumab
5219:
5200:
5140:Teprotumumab
5090:Inebilizumab
5085:Fontolizumab
5065:Atorolimumab
5033:T-lymphocyte
5031:
5005:
4989:
4975:
4956:
4945:Lerdelimumab
4940:Bertilimumab
4932:
4920:
4899:
4885:
4871:
4857:
4838:
4819:
4803:Pascolizumab
4788:Obinutuzumab
4787:
4780:
4766:
4752:
4736:Clenoliximab
4728:
4712:Otelixizumab
4699:
4672:
4659:Lebrikizumab
4643:
4627:
4611:
4595:
4579:
4536:Satralizumab
4526:Risankizumab
4458:
4417:
4401:
4393:Serum target
4345:Temsirolimus
4271:
4262:Pomalidomide
4257:Lenalidomide
4215:Pimecrolimus
4194:
4168:Methotrexate
4160:
4138:
4125:Azathioprine
4117:
4102:(initiation)
3893:Sibrotuzumab
3858:Parsatuzumab
3843:Otlertuzumab
3838:Odronextamab
3833:Ocaratuzumab
3828:Obinutuzumab
3827:
3803:Lumretuzumab
3758:Flotetuzumab
3753:Ficlatuzumab
3748:Farletuzumab
3743:Etaracizumab
3728:Emibetuzumab
3615:Zolbetuximab
3590:Margetuximab
3570:Girentuximab
3432:Minretumomab
3397:Blinatumomab
3336:Teprotumumab
3316:Seribantumab
3141:Botensilimab
3126:Atezolizumab
3111:Adecatumumab
3000:Pexidartinib
2985:Odronextamab
2955:Gilteritinib
2935:Cabozantinib
2882:
2848:
2823:
2817:Temsirolimus
2799:
2783:
2765:proapoptotic
2763:
2747:
2726:Zanubrutinib
2698:
2668:
2637:
2614:Lestaurtinib
2593:Janus kinase
2591:
2572:
2526:
2519:Non-receptor
2500:Cabozantinib
2493:
2462:Infigratinib
2447:
2421:
2363:Fruquintinib
2345:
2338:Gilteritinib
2334:Lestaurtinib
2327:
2276:
2245:
2218:Mobocertinib
2183:Aumolertinib
2171:
2136:Tremelimumab
2121:Tislelizumab
2076:Retifanlimab
1951:Blinatumomab
1921:Atezolizumab
1892:
1874:
1864:
1846:Obinutuzumab
1845:
1824:
1806:
1773:
1756:
1714:
1697:
1617:
1605:
1580:. Retrieved
1566:
1554:. Retrieved
1542:
1530:
1518:. Retrieved
1504:
1492:. Retrieved
1483:
1474:
1464:16 September
1462:. Retrieved
1451:
1442:
1430:. Retrieved
1416:
1383:
1379:
1356:
1344:. Retrieved
1340:the original
1330:
1311:
1287:10.1038/6179
1278:
1274:
1268:
1235:
1231:
1225:
1188:
1184:
1174:
1145:
1141:
1135:
1098:
1094:
1084:
1072:. Retrieved
1063:
1037:cite journal
1025:. Retrieved
1005:
1001:
991:
959:(4): 370–4.
956:
952:
923:. Retrieved
914:
892:16 September
890:. Retrieved
881:
849:. Retrieved
840:
831:
819:. Retrieved
811:
802:
794:the original
762:
733:
709:
701:bendamustine
694:
683:
672:
660:chlorambucil
653:
642:
631:
623:
592:
577:
568:
559:
544:
541:Side effects
536:
528:bendamustine
525:
513:chlorambucil
510:
507:Medical uses
489:
486:Obinutuzumab
485:
484:
473:
467:
292:Elimination
234:Legal status
228:Legal status
153:Obinutuzumab
117:License data
23:Obinutuzumab
18:
5479:Tofacitinib
5419:Ravulizumab
5409:Pirfenidone
5399:Peficitinib
5299:Canakinumab
5289:Briakinumab
5279:Bimekizumab
5274:Baricitinib
5239:Aflibercept
5150:Vepalimomab
5145:Vapaliximab
5120:Rovelizumab
5110:Pexelizumab
5100:Morolimumab
5075:Cedelizumab
5060:Anifrolumab
5055:Alemtuzumab
5013:Basiliximab
4983:Tocilizumab
4969:Vedolizumab
4964:Natalizumab
4950:Metelimumab
4893:Gavilimomab
4851:Toralizumab
4846:Teneliximab
4832:Lumiliximab
4827:Gomiliximab
4813:Ublituximab
4793:Ocrelizumab
4746:Zanolimumab
4722:Visilizumab
4680:Secukinumab
4664:Ustekinumab
4635:Elsilimomab
4619:Faralimomab
4587:Mepolizumab
4571:Ustekinumab
4566:Tocilizumab
4541:Secukinumab
4491:Canakinumab
4481:Briakinumab
4476:Bimekizumab
4471:Basiliximab
4460:Interleukin
4450:Nerelimomab
4355:Zotarolimus
4296:(reception)
4267:Thalidomide
4225:Voclosporin
4210:Ciclosporin
4204:Calcineurin
4200:Cyclophilin
4147:Leflunomide
4143:inhibitors
4026:from market
4001:Ontuxizumab
3975:Ertumaxomab
3970:Catumaxomab
3942:Vanucizumab
3922:+deruxtecan
3918:Trastuzumab
3913:Tigatuzumab
3848:Onartuzumab
3823:Nimotuzumab
3813:Milatuzumab
3783:Labetuzumab
3773:Imgatuzumab
3738:Epcoritamab
3723:Emactuzumab
3708:Dalotuzumab
3698:Dacetuzumab
3678:Cirmtuzumab
3653:Bevacizumab
3638:Alemtuzumab
3610:Ublituximab
3560:Ensituximab
3555:Ecromeximab
3550:Dinutuximab
3535:Carotuximab
3525:Bavituximab
3502:Tositumomab
3497:Tenatumomab
3467:Racotumomab
3412:Edrecolomab
3387:Arcitumomab
3356:Zalutumumab
3346:Vantictumab
3321:Sugemalimab
3311:Robatumumab
3306:Rilotumumab
3301:Ramucirumab
3276:Panitumumab
3251:Necitumumab
3241:Mapatumumab
3236:Lucatumumab
3231:Lexatumumab
3221:Istiratumab
3206:Intetumumab
3191:Flanvotumab
3186:Figitumumab
3171:Dusigitumab
3166:Duligotumab
3156:Daratumumab
3151:Conatumumab
3146:Cixutumumab
3136:Balstilimab
3116:Amivantamab
3030:Tebentafusp
3010:Regorafenib
3005:Quizartinib
2995:Pemigatinib
2975:Midostaurin
2950:Erdafitinib
2945:Entrectinib
2928:Parsaclisib
2876:Trilaciclib
2866:Palbociclib
2861:Dalpiciclib
2856:Abemaciclib
2758:Aflibercept
2685:Entrectinib
2655:Selumetinib
2650:Cobimetinib
2645:Binimetinib
2629:Ruxolitinib
2619:Momelotinib
2599:Baricitinib
2497:inhibitors:
2474:Pralsetinib
2470:Pemigatinib
2458:Futibatinib
2454:Entrectinib
2451:inhibitors:
2383:Regorafenib
2287:Avapritinib
2233:Rociletinib
2228:Osimertinib
2193:Dacomitinib
2131:Toripalimab
2116:Teclistamab
2106:Talquetamab
2101:Tafasitamab
2096:Sugemalimab
2091:Serplulimab
2081:Sabatolimab
2071:Ramucirumab
2066:Prolgolimab
2036:Necitumumab
1991:Epcoritamab
1971:Dostarlimab
1961:Daratumumab
1916:Amivantamab
1881:Alemtuzumab
1871:Brentuximab
1861:Tositumomab
1836:Ibritumomab
1817:Elranatamab
1780:Bevacizumab
1768:Edrecolomab
1763:Catumaxomab
1725:Trastuzumab
1709:Panitumumab
1556:22 November
679:NHS England
645:Biogen Idec
636:to develop
611:mannosidase
551:hepatitis B
461: g·mol
319:949142-50-1
304:Identifiers
90:Other names
81:Trade names
5521:Categories
5469:Sutimlimab
5464:Spesolimab
5449:Siltuximab
5389:Olokizumab
5379:Ixekizumab
5374:Itacitinib
5364:Guselkumab
5359:Fingolimod
5354:Filgotinib
5304:Crovalimab
5294:Brodalumab
5284:Blisibimod
5249:Rilonacept
5232:Opinercept
5227:Etanercept
5213:Belatacept
5164:Polyclonal
5125:Siplizumab
5115:Reslizumab
5105:Ofatumumab
5095:Maslimomab
5080:Emapalumab
5023:Inolimomab
5018:Daclizumab
4997:Odulimomab
4912:Ruplizumab
4907:Frexalimab
4865:Aselizumab
4760:Efalizumab
4717:Teplizumab
4613:Interferon
4603:Omalizumab
4556:Spesolimab
4546:Siltuximab
4521:Rilonacept
4516:Olokizumab
4506:Ixekizumab
4501:Guselkumab
4496:Daclizumab
4486:Brodalumab
4445:Infliximab
4430:Afelimomab
4425:Adalimumab
4409:Eculizumab
4385:Monoclonal
4376:Antibodies
4350:Umirolimus
4330:Everolimus
4279:Apremilast
4239:Gusperimus
4220:Tacrolimus
4188:inhibitors
4180:Macrolides
4162:antifolate
3947:Veltuzumab
3926:+emtansine
3898:Simtuzumab
3863:Pertuzumab
3793:Lintuzumab
3768:Glofitamab
3718:Elotuzumab
3703:Demcizumab
3643:Axatilimab
3633:Abituzumab
3605:Siltuximab
3580:Isatuximab
3520:Amatuximab
3492:Pintumomab
3462:Pemtumomab
3457:Oregovomab
3392:Bectumomab
3372:Abagovomab
3326:Tarextumab
3296:Radretumab
3291:Pritumumab
3281:Patritumab
3271:Olaratumab
3266:Ofatumumab
3256:Nesvacumab
3246:Narnatumab
3216:Iratumumab
3211:Ipilimumab
3181:Enoticumab
3161:Drozitumab
3089:for tumors
3045:Venetoclax
3040:Vandetanib
3015:Ripretinib
2980:Nintedanib
2965:Lenvatinib
2940:Capmatinib
2923:Idelalisib
2913:Copanlisib
2886:inhibitors
2871:Ribociclib
2842:Vismodegib
2827:inhibitors
2807:Everolimus
2773:prohibitin
2690:Lorlatinib
2680:Crizotinib
2660:Trametinib
2624:Pacritinib
2609:Filgotinib
2604:Fedratinib
2508:Crizotinib
2504:Capmatinib
2486:Vandetanib
2434:Brigatinib
2413:Vandetanib
2373:Nintedanib
2368:Lenvatinib
2307:Ripretinib
2238:Vandetanib
2213:Lazertinib
2188:Brigatinib
2111:Tarlatamab
2046:Olaratumab
2006:Isatuximab
2001:Ipilimumab
1981:Elotuzumab
1976:Durvalumab
1956:Cemiplimab
1946:Bermekimab
1936:Axatilimab
1851:Ofatumumab
1831:Glofitamab
1813:Glofitamab
1721:Pertuzumab
1325:, page 123
1238:(1): 6–7.
1191:: 805697.
1101:: 805697.
821:22 October
754:References
609:and Golgi
603:engineered
549:warnings:
521:venetoclax
450:Molar mass
375:O43472U9X8
350:ChemSpider
310:CAS Number
16:Medication
5459:Sirukumab
5454:Siponimod
5439:Sarilumab
5414:Ponesimod
5384:Netakimab
5369:Iptacopan
5349:Etrasimod
5309:Danicopan
5244:Alefacept
5208:Abatacept
5130:Talizumab
5070:Begelomab
4926:Belimumab
4879:Galiximab
4808:Rituximab
4774:Erlizumab
4741:Keliximab
4551:Sirukumab
4531:Sarilumab
4511:Netakimab
4440:Golimumab
4340:Sirolimus
4036:Phase III
4024:Withdrawn
3818:Naxitamab
3808:Matuzumab
3625:Humanized
3600:Rituximab
3565:Futuximab
3540:Cetuximab
3477:Solitomab
3437:Mitumomab
3427:Lilotomab
3407:Detumomab
3351:Votumumab
3341:Tovetumab
3261:Nivolumab
3226:Icrucumab
3196:Ganitumab
3035:Tepotinib
3025:Sunitinib
3020:Sorafenib
2990:Pazopanib
2970:Masitinib
2918:Duvelisib
2908:Alpelisib
2896:Sotorasib
2891:Adagrasib
2837:Sonidegib
2832:Glasdegib
2778:Adipotide
2711:Ibrutinib
2584:Dasatinib
2579:Bosutinib
2564:Radotinib
2559:Ponatinib
2554:Nilotinib
2544:Dasatinib
2539:Bosutinib
2534:Asciminib
2502:(VEGFR),
2460:(FGFR2),
2439:Ceritinib
2429:Alectinib
2408:Toceranib
2403:Tivozanib
2398:Sunitinib
2393:Sorafenib
2388:Semaxanib
2378:Pazopanib
2358:Cediranib
2322:Toceranib
2317:Sunitinib
2312:Sorafenib
2302:Pazopanib
2297:Masitinib
2264:Tucatinib
2259:Neratinib
2254:Lapatinib
2223:Olmutinib
2203:Gefitinib
2198:Erlotinib
2173:HER1/EGFR
2041:Nivolumab
2031:Naxitamab
1856:Rituximab
1704:Cetuximab
1699:HER1/EGFR
1494:3 October
1074:5 October
925:5 October
716:ibrutinib
613:2, which
588:rituximab
574:Chemistry
547:black box
299:28.4 days
294:half-life
190:Routes of
164:Pregnancy
109:Monograph
103:Drugs.com
52:Humanized
5511:Medicine
5394:Ozanimod
5269:Avacopan
5262:Unsorted
5048:Unsorted
4958:Integrin
4691:Cellular
4466:Anakinra
4312:Anakinra
4234:Abetimus
4086: /
3512:Chimeric
3422:Igovomab
2825:hedgehog
2787:against
2785:exotoxin
2751:against
2700:Bruton's
2549:Imatinib
2472:(FGFR),
2468:(NTRK),
2353:Axitinib
2292:Axitinib
2248:HER2/neu
2208:Icotinib
2178:Afatinib
2152:("-nib")
1931:Avelumab
1803:lymphoid
1795:lymphoma
1791:Leukemia
1716:HER2/neu
1678:("-mab")
1576:Archived
1547:Archived
1520:14 March
1514:Archived
1488:Archived
1458:Archived
1426:Archived
1408:40983655
1400:24338113
1346:29 April
1319:Archived
1303:20078393
1295:10052355
1260:26281173
1252:24406911
1217:35222385
1166:37678236
1127:35222385
1068:Archived
1022:31166681
983:26705497
919:Archived
886:Archived
882:DailyMed
851:10 April
845:Archived
770:Archived
730:Research
599:produced
476:(verify)
330:DrugBank
204:ATC code
166:category
148:DailyMed
5190:-cept (
2528:bcr-abl
1889:myeloid
1484:PM Live
1432:20 July
1208:8873567
1118:8873567
1027:11 June
974:4677809
776:, p 176
628:History
584:epitope
411:Formula
339:DB08935
266:Rx-only
263:WARNING
220:)
214: (
212:L01FA03
179: C
150::
133::
5497:Portal
5202:CTLA-4
5192:Fusion
4693:target
4674:IL-17A
4651:, and
4184:other
4019:WHO-EM
1775:VEGF-A
1582:4 June
1406:
1398:
1301:
1293:
1258:
1250:
1215:
1205:
1164:
1125:
1115:
1020:
981:
971:
490:Gazyva
395:D09321
260:
247:
146:
136:by INN
129:
64:Target
54:(from
47:Source
4991:LFA-1
4901:CD154
4754:CD11a
4653:IL-23
4649:IL-13
4645:IL-12
4249:IMiDs
3365:Mouse
3104:Human
3096:Tumor
2769:ANXA2
2741:Other
2639:MAP2K
2510:(ALK)
2495:c-MET
2347:VEGFR
2282:PDGFR
2278:C-kit
1909:Other
1758:EpCAM
1550:(PDF)
1539:(PDF)
1404:S2CID
1380:Drugs
1299:S2CID
1256:S2CID
607:MGAT3
601:were
501:Roche
425:10060
56:mouse
4921:BLyS
4873:CD80
4840:CD40
4821:CD23
4782:CD20
4768:CD18
4629:IL-6
4322:mTOR
4196:FKBP
4186:IL-2
2884:KRAS
2789:IL-2
2771:and
2753:VEGF
2670:EML4
2329:FLT3
2280:and
2168:ErbB
1894:CD33
1876:CD52
1866:CD30
1826:CD20
1694:ErbB
1584:2019
1558:2015
1522:2016
1496:2014
1466:2020
1434:2015
1396:PMID
1348:2015
1291:PMID
1248:PMID
1213:PMID
1162:PMID
1123:PMID
1076:2023
1043:link
1029:2024
1018:PMID
1002:NEJM
979:PMID
927:2023
894:2020
853:2023
823:2023
744:CHOP
675:NICE
494:CD20
437:2020
431:1712
419:6512
386:KEGG
366:UNII
357:none
286:data
99:AHFS
69:CD20
37:Type
4934:CAT
4730:CD4
4701:CD3
4419:TNF
4092:L04
2674:ALK
2574:Src
2449:RET
2423:ALK
1873:),
1863:),
1823:),
1808:CD3
1664:L01
1388:doi
1283:doi
1240:doi
1203:PMC
1193:doi
1158:PMC
1150:doi
1113:PMC
1103:doi
1010:doi
1006:380
969:PMC
961:doi
816:FDA
459:.72
457:064
455:146
217:WHO
131:EMA
5523::
4647:,
4032::
3924:/
2506:,
2476:,
2464:,
2336:,
2275::
2170::
1891::
1819:,
1815:,
1805::
1723:,
1696::
1673:CI
1658:/
1616:.
1604:.
1574:.
1541:.
1482:.
1450:.
1402:.
1394:.
1384:74
1382:.
1368:^
1297:.
1289:.
1279:17
1277:.
1254:.
1246:.
1236:32
1234:.
1211:.
1201:.
1189:13
1187:.
1183:.
1156:.
1146:18
1144:.
1121:.
1111:.
1099:13
1097:.
1093:.
1062:.
1051:^
1039:}}
1035:{{
1016:.
1004:.
1000:.
977:.
967:.
955:.
951:.
935:^
913:.
902:^
880:.
861:^
839:.
814:.
810:.
781:^
621:.
590:.
557:.
523:.
503:.
443:44
271:EU
256:US
249:S4
243:AU
175:AU
143:US
126:EU
5499::
5345:)
5341:(
5194:)
5040:)
5036:(
4799:)
4795:(
4202:/
4198:/
4182:/
4094:)
4090:(
4076:e
4069:t
4062:v
3928:)
3920:(
3132:)
3128:(
3079:e
3072:t
3065:v
2796:)
2792:(
2780:)
2776:(
2760:)
2756:(
2672:-
2586:)
2577:(
2332:(
2324:)
2285:(
2240:)
2176:(
1927:)
1923:(
1901:)
1897:(
1883:)
1879:(
1869:(
1829:(
1811:(
1793:/
1782:)
1778:(
1770:)
1761:(
1742:)
1731:)
1727:(
1719:(
1711:)
1702:(
1666:)
1662:(
1648:e
1641:t
1634:v
1586:.
1560:.
1524:.
1498:.
1468:.
1436:.
1410:.
1390::
1350:.
1305:.
1285::
1262:.
1242::
1219:.
1195::
1168:.
1152::
1129:.
1105::
1078:.
1045:)
1031:.
1012::
985:.
963::
957:6
929:.
896:.
855:.
825:.
722:/
440:S
434:O
428:N
422:H
416:C
273::
258::
245::
177::
101:/
58:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.